Please login to the form below

From ideals to execution – exploring the realities of patient-centricity

The Ashfield Patients & Pharma Future Forum explores the reality of patient-centricity in 2016 and what’s next for pharma.

Since eyeforpharma, Barcelona 2015, we have heard industry, vendors, specialists, advocacy groups and patients talking about patient-centricity: what is it? What does it mean for the industry and the wider healthcare environment? What does it mean for patients? What will it look like in the future?  

However, one question that’s been missing recently is “Why does it matter?” The reason this question is no longer prominent is that we have moved past the phase where we are looking for a rationale to drive towards a more patient-centric industry, and we are now actually trying to shape, deliver and measure it.  

We wanted to understand how the industry was moving from vision to reality in patient-centricity. What we wanted to understand was the reality of patient-centricity today, the truth behind the buzzwords and challenges in delivering this vision. Who better to ask than industry representatives?  

We convened a panel of 12 representatives from pharmaceutical companies, including large broad portfolio companies as well as smaller/mid-sized more specialist providers, in a mix of patient-centred roles from Chief Patient Officer through to regional and functional patient leads. We ran a 2-week online expert panel earlier this year, inviting our panel to discuss, as openly as possible, their company vision, the strategy and structure that they were putting in place for delivering the vision, and the key challenges they had found in moving towards patient-centricity. The panel was moderated by Andrew Schorr of Patient Power, along with Ashfield Healthcare Communications.  

Click here to download our “From ideals to execution” whitepaper
 to learn more about the insights shared during our Patients & Pharma Future Forum and what’s next for pharma.

7th July 2016



Company Details


Contact Website

Ashfield House
Resolution Road
Ashby de la Zouch
LE65 1HW

Latest content on this profile

Ashfield wins Best Newcomer at the Pf Awards 2018
We are thrilled to announce that Zuchaela Smylie, from Ashfield, won Best Newcomer at the 2018 Pf Awards, the largest pharmaceutical sales awards in the UK. The awards ceremony took place on Thursday, 9 March at The Lancaster Hotel in London.
“It is evident that meeting face-to-face is still highly valued in the digital age”
Attending a scientific congress or meeting overtakes professional journals and publications as the educational channel of choice for Healthcare Professionals – according to findings of new study
Ashfield to present at the Orphan Drugs for Rare Diseases Summit
Ashfield has a breadth of experience with orphan drugs and we are passionate about helping to improve the lives of people living with rare diseases. We are delighted to be sponsoring and presenting at the ‘Orphan Drugs for Rare Diseases’ event 22-23 March in Berlin.
Addressing the biggest challenges for rare disease communities
Each year, Rare Disease Day takes place worldwide on the last day in February. The main objective of Rare Disease Day is to raise awareness amongst the general public, the healthcare industry and decision-makers about rare diseases and their impact on patients' lives.
Humanise is our strategic approach to healthcare communications. It’s based on the need to understand. It looks at the emotions that make us human. It examines the feelings we have as individuals. It defines the behaviours we show as people.
Ashfield launches new commercial model to improve ROI
Ashfield, part of UDG Healthcare, a global leader in providing outsourced healthcare services, has announced the launch of a pioneering new commercial model called The Ashfield Solution.